# Sage Therapeutics Inc. (SAGE)

Source: https://www.quantisnow.com/company/SAGE
Generated: 2026-11-12T11:27:23.704Z

- Ticker: SAGE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: sagerx.com

## About

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

## Latest SAGE news and filings

- 2025-08-11 21:00 UTC [SEC Form 15-12G filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-sage-therapeutics-inc-6158865)
- 2025-08-01 21:22 UTC [SEC Form POSASR filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-sage-therapeutics-inc-6143368)
- 2025-08-01 21:21 UTC [SEC Form POSASR filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-sage-therapeutics-inc-6143364)
- 2025-08-01 21:21 UTC [SEC Form POSASR filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-sage-therapeutics-inc-6143363)
- 2025-08-01 21:21 UTC [SEC Form POSASR filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-sage-therapeutics-inc-6143360)
- 2025-08-01 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143353)
- 2025-08-01 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143351)
- 2025-08-01 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143350)
- 2025-08-01 21:19 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143346)
- 2025-08-01 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143345)
- 2025-08-01 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143343)
- 2025-08-01 21:18 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143342)
- 2025-08-01 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143340)
- 2025-08-01 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143339)
- 2025-08-01 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143336)
- 2025-08-01 21:17 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143334)
- 2025-08-01 21:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143333)
- 2025-08-01 21:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143329)
- 2025-08-01 21:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143325)
- 2025-08-01 21:15 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-sage-therapeutics-inc-6143322)
- 2025-07-31 16:04 UTC [SEC Form 4] [Officer Quirk Michael C. returned 32,961 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-quirk-michael-c-returned-32961-shares-to-the-company-6140579)
- 2025-07-31 16:03 UTC [SEC Form 4] [SEC Form 4 filed by Director Federer Jessica](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-federer-jessica-6140577)
- 2025-07-31 15:57 UTC [SEC Form 4] [Chief Operating Officer Benecchi Christopher returned 64,428 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-operating-officer-benecchi-christopher-returned-64428-shares-to-the-6140565)
- 2025-07-31 15:52 UTC [SEC Form 4] [SEC Form 4 filed by Director Cola Michael F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cola-michael-f-6140560)
- 2025-07-31 15:48 UTC [SEC Form 4] [Director Barrett Elizabeth A. closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-barrett-elizabeth-a-closing-all-direct-ownership-in-the-6140554)
- 2025-07-31 15:42 UTC [SEC Form 4] [Director Golumbeski George closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-golumbeski-george-closing-all-direct-ownership-in-the-company-6140548)
- 2025-07-31 15:38 UTC [SEC Form 4] [SEC Form 4 filed by Director Germano Geno J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-germano-geno-j-6140547)
- 2025-07-31 15:28 UTC [SEC Form 4] [Director Frates James M closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-frates-james-m-closing-all-direct-ownership-in-the-6140539)
- 2025-07-31 15:22 UTC [SEC Form 4] [Officer Shiferman Gregory L. returned 23,735 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-shiferman-gregory-l-returned-23735-shares-to-the-company-6140534)
- 2025-07-31 15:17 UTC [SEC Form 4] [President and CEO Greene Barry E returned 53,229 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-greene-barry-e-returned-53229-shares-to-6140529)
- 2025-07-31 13:34 UTC [SEC Form 25-NSE filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-sage-therapeutics-inc-6140412)
- 2025-07-31 13:17 UTC [SEC Schedule 14D-9] [Amendment: SEC Form SC 14D9/A filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-14d9a-filed-by-sage-therapeutics-inc-6140380)
- 2025-07-31 13:14 UTC [SEC Form 8-K] [Sage Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update](https://www.quantisnow.com/insight/sage-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6140370)
- 2025-07-31 13:06 UTC [SEC Schedule TOT] [Amendment: SEC Form SC TO-T/A filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-to-ta-filed-by-sage-therapeutics-inc-6140355)
- 2025-07-31 12:44 UTC [Mergers & Acquisitions] [Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics](https://www.quantisnow.com/insight/supernus-pharmaceuticals-completes-acquisition-of-sage-therapeutics-6140250)
- 2025-07-30 21:56 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-sage-therapeutics-inc-6139281)
- 2025-07-30 20:20 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sage-therapeutics-inc-6138824)
- 2025-07-30 20:09 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sage-therapeutics-inc-6138578)
- 2025-07-30 20:05 UTC [Earnings Date] [Sage Therapeutics Announces Second Quarter 2025 Financial Results](https://www.quantisnow.com/insight/sage-therapeutics-announces-second-quarter-2025-financial-results-6138426)
- 2025-07-29 18:32 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Sage Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-sage-therapeutics-inc-6136199)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SAGE
- Earnings history: https://www.quantisnow.com/earnings/SAGE
- Dividend history: https://www.quantisnow.com/dividends/SAGE
- Insider transactions: https://www.quantisnow.com/insiders/SAGE
- Options chain: https://www.quantisnow.com/options/SAGE
- SEC 8-K filings only: https://www.quantisnow.com/company/SAGE/8-k
- RSS and alerts for SAGE: https://www.quantisnow.com/docs/rss-feeds.md